Adding up to this knowledge, Li et al. developed a point-of-care lateral flow immunoassay (LFIA) that detects simultaneously the presence in human blood of IgG and IgM due to COVID-19 within 15 min owing to the interaction of these antibodies with SARS-CoV-2 recombinant proteins—acting as antigens—that are adsorbed onto the surface of 40 nm-colloidal AuNPs [189]. The gene discussed is CD40LG; the disease is COVID-19.